Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2023 · 10-Q
Revenue-$893.00K-$893.00KN/M vs Q2 2022 Net Income-$17.48M-$17.48MN/M vs Q2 2022 EPS, diluted—
Operating Income-$17,489,300N/M Operating Cash Flowderived-$16,340,800N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$16,365,200N/M Margins · derivedOperating margin1958.5%+5533.8 pt vs Q2 2022
Net margin1957.8%+5531.7 pt vs Q2 2022
ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end